Although it is the leading infectious cause of birth defects, patients and some doctors know little about cytomegalovirus.
Study is evaluating whether Triplex is safe and effective in improving the outcomes of liver transplant recipients MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (“Fortress”), an ...
Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta Therapeutics Inc.’s gene therapy, Elevidys ...
With no vaccine available, early detection, hygiene practices, and public education are vital to prevent long-term disabilities caused by Human Cytomegalovirus in Kashmir’s children Dr Umer Majeed ...
Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results